Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.

Jilin Huikang Pharmaceutical Co., Ltd., established on 2016-04-11, The business scope includes chemical raw materials,Pharmaceutical Intermediates,pharmaceutical production(The above does not contain hazardous chemicals);Pharmaceutical wholesale and retail;drug development;Drug information consultation and technical services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Suzhong Pharmaceutical Group Co., Ltd., established on 1979-11-26, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug retail;Drug import and export;Health food production;Health food sales;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of hygiene products and single-use medical products;Production of disinfection products for the prevention and control of infectious diseases;Disinfectant production(Free of Hazardous Chemicals);Production of sterile equipment;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Chinese herbal medicine planting;Chinese herbal medicine acquisition(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Nanjing Portai Pharmaceutical Technology Co., Ltd., established on 2013-03-14, Business scope includes western medicine,traditional Chinese medicine,Health products,Medical device research and development,Planning and technical services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of);Chemical product sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Boehringer Ingelheim Corporate Center GmbH, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Ingelheim am Rhein, Germany. The firm leases real estate properties. It was founded in 2016.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Shanghai Cell Therapy Group Co. Ltd. is a Chinese company located in Shanghai that operates as a cell therapy company. The firm was founded in 2013 by Jie Wei Li.\nThe company says this about itself: Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of \"changing the length and abundance of life with cell therapy\", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Shanghai Baize Biotechnology Co., Ltd., established on 2010-10-21, Business scope includes biological products,medicine,food research,to develop,And provide relevant technical advice,Technical Services,technology transfer,Class I medical device,Chemical raw materials,chemical reagent,laboratory reagent(In addition to the above hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Instrumentation,Sales of laboratory equipment,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Green Cross Co., Ltd. engages in the manufacture, sale, and rental of safety items. Its products include road safety materials, disaster prevention necessities, safety equipment, protection gear, and signboards and tags. The company was founded in January 1969 and is headquartered in Fukuoka, Japan.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Jiangsu Vcare PharmaTech Co., Ltd. is a company headquartered in Nanjing, China. The firm manufactures and sells pharmaceutical intermediates. It was founded in 2010. Yan Chun Gong is currently the CEO of the company.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.